Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors

Prior treatment

• Prior immunosuppressive chemotherapy, any immunotherapy other than a PD-1 inhibitor within 4 weeks of first study drug dose.

Other illness

• History of another malignancy within 3 years before the first dose of study drug or any evidence of residual disease from a previously diagnosed malignancy.

Other

• Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis.

• Participants must have
  • Metastatic squamous or nonsquamous non-small cell lung cancer (NSCLC) (without known targetable EGFR, ALK, ROS1, or BRAF mutations) who either
  • a) have not yet received frontline therapy for metastatic disease and without prior exposure to anti PD-1/PD-L1 or
  • b) are relapsed/refractory with progression on anti PD-1/PD therapy.
  • Relapsed/refractory metastatic cutaneous melanoma (regardless of mutation status) with progression on a PD-1 inhibitor
  • Metastatic head and neck squamous cell carcinoma (HNSCC) who have not yet received frontline therapy for metastatic disease and without prior exposure to a PD-1/PD-L1 inhibitor.
• Cohorts 1-4 only: Melanoma participants must be currently on PD-1 checkpoint inhibitor (CPI) therapy (e.g. nivolumab or pembrolizumab) or had their last dose of PD-1 CPI containing therapy as the last previous line of therapy within 90 days prior to enrollment; PD-1 CPI therapy must be the immediate prior line of treatment.
• Cohorts 1-4 only: Participants must have progressed on treatment with an anti-PD-1 monoclonal antibody (mAb) administered either as monotherapy, or in combination with other CPIs or other therapies. PD-1 treatment progression is defined by meeting all of the following criteria.
  • Have received at least 2 doses of an approved PD-1 inhibitor.
  • Have demonstrated disease progression (PD) after a PD-1 inhibitor as defined by RECIST v1.1.
  • Progressive disease has been documented within 90 days from the last dose of PD-1 inhibitor.
  • Participants with melanoma will need iRECIST confirmation of progression with a second assessment at least four weeks after the initial date of progressive disease
  • NSCLC participants on PD-1 inhibitor containing therapy for less than 90 days will need iRECIST confirmation of progression at least 4 weeks after the initial date of progressive disease
• Tumor tissue sample obtained within 3 months prior to enrollment is required, and no systemic anticancer therapy given after the sample was obtained.
• An Eastern Cooperative Oncology Group (ECOG) Performance Status score of equal or less than 1